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SUMMARY
Zika virus (ZIKV) causes severe neurologic complications and fetal aberrations. Vaccine 
development is hindered by potential safety concerns due to antibody cross-reactivity with dengue 
virus and the possibility of disease enhancement. In contrast, passive administration of anti-ZIKV 
antibodies engineered to prevent enhancement may be safe and effective. Here, we report on 
human monoclonal antibody Z021, a potent neutralizer that recognizes an epitope on the lateral 
ridge of the envelope domain III (EDIII) of ZIKV and is protective against ZIKV in mice. When 
administered to macaques undergoing a high-dose ZIKV challenge, a single anti-EDIII antibody 
selected for resistant variants. Co-administration of two antibodies, Z004 and Z021, which target 
distinct sites on EDIII, was associated with a delay and a 3- to 4-log decrease in peak viremia. 
Moreover, the combination of these antibodies engineered to avoid enhancement prevented viral 
escape due to mutation in macaques, a natural host for ZIKV.
In Brief
Passive administration of anti-Zika human monoclonal antibodies could be an efficacious and safe 
alternative to vaccines for at-risk populations. Keeffe et al. show that administration of a 
combination of two monoclonal antibodies to macaques followed by high-dose intravenous Zika 
challenge reduces viremia and prevents the emergence of viral escape mutations.
Graphical Abstract
INTRODUCTION
Zika virus (ZIKV) is a member of the Flavivirus genus, which includes four serotypes of 
dengue virus (DENV1–4), West Nile virus (WNV), yellow fever virus (YFV), and other 
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vector-borne viruses that cause human morbidity and mortality (Weaver and Reisen, 2010). 
ZIKV causes mild symptoms consisting of fever, headache, rash, conjunctivitis, and 
arthralgia in an estimated 20% of infected individuals. In addition, infection is occasionally 
associated with severe neurologic problems that require hospitalization, such as 
meningoencephalitis or the immune-mediated Guillain-Barré syndrome (Miner and 
Diamond, 2017; Muñoz et al., 2016). The most severe consequences of infection are 
manifest in fetuses, which can develop devastating developmental aberrations, including 
microcephaly, collectively referred to as congenital Zika syndrome (Brasil et al., 2016; Del 
Campo et al., 2017). Infection of macaques, a natural host of ZIKV, during pregnancy 
frequently leads to fetal demise (Dudley et al., 2018), and in some non-human primate 
models, prenatal and early postnatal infection is associated with fetal and infant 
neuropathology and persistent functional and behavioral abnormalities (Coffey et al., 2018; 
Mavigner et al., 2018).
There are no approved treatments for ZIKV. Vaccines for ZIKV are under development, but 
the path to approval may be exceedingly difficult because of antibody cross-reactivity with 
other flaviviruses and the possibility of disease enhancement (Bardina et al., 2017; George et 
al., 2017; Halstead, 2018; Harrison, 2016; Heinz and Stiasny, 2017; Katzelnick et al., 2017; 
Salje et al., 2018; Stettler et al., 2016). Passive administration of monoclonal antibodies 
represents an alternative approach to vaccines because human monoclonal antibodies can 
effectively neutralize the virus in vitro and protect against ZIKV infection in mice 
(Fernandez et al., 2017; Robbiani et al., 2017; Sapparapu et al., 2016; Stettler et al., 2016; 
Swanstrom et al., 2016; Yu et al., 2017). In addition, antibodies can be engineered to prevent 
interaction with Fcγ receptors that mediate enhancement and thus minimize the risk of 
disease enhancement (Beltramello et al., 2010).
A combination of three antibodies targeting epitopes on the ZIKV envelope domain II and 
III regions was recently shown to be effective at preventing viremia in macaques (Magnani 
et al., 2017b), although the same three antibodies in combination failed to prevent virus 
transmission to the fetus (Magnani et al., 2018). Moreover, it was reported that a single 
antibody to a conformational epitope prevents ZIKV viremia for 7 days after low-dose 
challenge (Abbink et al., 2018), but viremia was not evaluated for longer periods of time or 
upon high-dose viral challenge.
Here, we investigate the efficacy of the potent anti-envelope domain III (EDIII) antibody 
Z004 (Robbiani et al., 2017) against high-dose viral challenge in macaques over an extended 
time period, as well as molecularly characterize a second human anti-EDIII monoclonal 
antibody, Z021, and examine its protective activity in combination with Z004.
RESULTS
Z004 is one of several human monoclonal antibodies that were isolated from an individual 
with high levels of serum neutralizing activity against ZIKV (Robbiani et al., 2017). Z004 
has strong activity against ZIKV and DENV1 in vitro and protects Ifnar1−/− mice from lethal 
ZIKV challenge (Robbiani et al., 2017). To determine whether Z004 is efficacious against 
ZIKV in primates, we administered it to rhesus macaques 24 hr before high-dose 
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intravenous challenge (105 plaque forming units [PFUs]) with a Brazilian strain of ZIKV. 
Infection was monitored by qRT-PCR to detect viral RNA in the plasma (Figure 1A). All 
four control animals developed viremia, which peaked on day 3, with plasma viral loads 
ranging from 105 to 107 RNA copies/mL (Figure 1A, black). In controls, viremia cleared 
spontaneously beginning on day 6 (Figure 1A; Coffey et al., 2017). In contrast, the Z004-
treated macaques showed delayed and prolonged viremia, with viral loads reaching only 3 3 
103 to 5 3 105 RNA copies/mL (Figure 1A, red). Thus, Z004 alone alters the course of ZIKV 
infection and leads to decreased but prolonged viremia.
To determine whether the viremia in Z004-treated animals was associated with viral escape 
mutations, we sequenced the antibody target region EDIII of the virus recovered from the 
plasma of the treated macaques on days 7 and 10. In both animals, the circulating viruses 
contained mutations in the EDIII (K394R in one animal and E393D or K394R in the other) 
(Figures 1B and 1C). Viruses encoding mutations were not observed in the untreated 
controls or in the inoculum (data not shown). While D393 is present in ZIKV strains of 
African origin, R394 has not been reported in the Virus Pathogen Resource database (ViPR; 
May 24, 2018). ELISA assays using ZIKV EDIIIE393D and EDIIIK394R mutant proteins 
confirmed that these mutations interfere with Z004 binding (Figure 1D). In contrast to the 
macaques, antibody resistance mutations were rare in Ifnar1−/− mice treated with Z004; 
nevertheless, the only mouse in a cohort of eight that developed mutations had the same 
K394R substitution observed in macaques (Figure S1). We conclude that high-dose 
intravenous ZIKV challenge in the presence of a single monoclonal antibody, Z004, leads to 
selection of resistant viral mutants.
Z021 is another human monoclonal antibody that, like Z004, was isolated from an individual 
with exceptionally high serum neutralizing activity against ZIKV (Robbiani et al., 2017). 
Z021 binds to the EDIII of both ZIKV and DENV1, neutralizes ZIKV reporter viral particles 
(RVPs) bearing Asian/American or African lineage E proteins with a half maximal 
inhibitory concentration (IC50) of 1 ng/mL and 0.7 ng/mL, respectively (Figure 2A; 
Robbiani et al., 2017), and has strong activity in plaque reduction neutralization test (PRNT) 
using an infectious Puerto Rican strain of ZIKV (IC50 of 4 ng/mL; Figure 2B). Like Z004, 
Z021 is also a potent neutralizer of DENV1 (IC50 of 10.1 ng/mL; Figure 2C).
To determine whether Z021 is effective against ZIKV in vivo, we administered Z021 to 
Ifnar1−/− mice either 24 hr before or 24 hr after ZIKV challenge (Figure 2D). Whereas all 
control mice developed symptoms and died (n = 11, Figure 2E), only 15% succumbed to 
infection when Z021 was administered before infection (n = 13; p = 0.0002 for disease and p 
< 0.0001 for survival; Figure 2E). Moreover, only 42% developed symptoms and 33% 
succumbed to disease when the antibody was administered 1 day after infection (n = 12; p = 
0.0006 for disease and p = 0.0002 for survival; Figure 2F). We conclude that Z021 is 
efficacious against ZIKV in vitro and protects Ifnar1−/− mice against lethal challenge.
Z004 binding to and neutralization of ZIKV and DENV1 is critically dependent on ZIKV 
EDIII residue K394 and also partially dependent on E393 (DENV1 residues K385 and 
E384, respectively; Figure 1D; Robbiani et al., 2017). To determine whether Z004 and Z021 
recognize distinct neutralizing epitopes on EDIII, we performed antigen competition ELISA 
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assays (Figure 2G; see STAR Methods). Each monoclonal antibody was incubated with 
saturating amounts of either wild-type ZIKV EDIII or an EDIII bearing mutations in the 
Z004 target site that interfere with its binding and neutralizing activity (EDIIIE393A/K394A; 
Figure 1D; Robbiani et al., 2017). Residual binding to wild-type EDIII was then measured 
by ELISA. Whereas Z004 binding to ZIKV was only blocked by wild-type ZIKV, binding of 
Z021 was blocked by both wild-type and ZIKV EDIIIE393A/K394A, indicating that residues 
E393 and K394 are critical for Z004, but not required for Z021 binding (Figure 2G). In 
agreement with this finding, Z004 failed to neutralize ZIKV RVPs that were altered to bear 
the E393A/K394A mutations while Z021 remained potent against the mutant RVPs in vitro 
(Figure 2H). To determine whether the Z004 and Z021 epitopes overlap, we performed 
antibody competition ELISA assays, which showed that the antigen-binding fragment (Fab) 
of Z021 did not bind to ZIKV EDIII immobilized by Z004 immunoglobulin G (IgG), and 
vice versa (Figure 2I; see STAR Methods). Thus, Z021 recognizes a neutralizing epitope on 
the EDIII that does not require E393-K394 but that is nearby or overlapping the epitope 
recognized by Z004.
To gain insight into how Z021 recognizes the Zika and dengue envelope proteins, we solved 
crystal structures of Z021 in complex with the EDIII of ZIKV and of DENV1 (Figure 3; 
Tables S1 and S2) and compared them to the previously obtained structures of the Z006 and 
Z004 antibodies in complex with the same viral antigens (Robbiani et al., 2017). Z021 
recognizes the lateral ridge of ZIKV and DENV1 EDIII and binds to both antigens in a 
similar orientation (Figure 3A). Although it recognizes the lateral ridge region of EDIII, 
Z021 does not bind to the same epitope as Z004 or the related Z006 but instead recognizes a 
distinct but overlapping epitope. When compared to Z004 (when bound to DENV1 EDIII) or 
Z006 (when bound to ZIKV EDIII), the Z021 Fab is rotated ~45° around an axis near the 
complementarity determining region 2 (CDRH2), positioning the heavy chains in similar 
regions, while the light chains exhibit divergent footprints (Figure 3B). Z021 makes heavy- 
and light-chain contact to the EDI-EDIII hinge region (the N-terminal end of the EDIII 
construct), the BC loop, and the DE loop of ZIKV EDIII, and heavy chain contacts to the FG 
loop. Notably, Z021 does not contact E393ZIKV or K394ZIKV, consistent with the 
biochemical data indicating that these residues are not required for Z021 activity (Figure 2). 
When compared to Z006, Z021 makes additional contacts to the EDI-EDIII hinge region and 
DE loops of ZIKV EDIII (Figure 3C). Thus, consistent with the ELISA and neutralization 
results (Figure 2), Z021 and Z004 recognize distinct but overlapping epitopes on EDIII.
To determine the efficacy of the combination of Z004 and Z021 against high-dose 
intravenous challenge with ZIKV, we co-administered the two antibodies to macaques 24 hr 
before infection. All three macaques developed delayed infections with low levels of viremia 
that peaked at 102–103 RNA copies/mL (Figures 4A and 4B). In contrast to macaques 
treated with Z004 alone (Figure 1), there were no mutations in the EDIII target site of the 
two antibodies (data not shown).
Late occurrence of viremia in some animals was not a consequence of rapid clearance of 
Z004 and Z021, since high levels of human antibodies were detectable in the macaque 
plasma (Figure S2). Similar results were obtained with Z004 and Z021 Fc mutant antibodies 
(GRLR) that are unable to mediate enhancement but maintain antiviral efficacy in vitro and 
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in mice (Figures S3 and S4): peak viral loads were comparable between wild-type and 
GRLR treated macaques (brown and green bars in Figure 4B) and no EDIII mutations were 
detected in either group. Although a trend for delayed peak viremia was observed in the 
macaques receiving the combination of wild-type antibodies (mean of 11 days versus 4 days 
in macaques receiving GRLR antibodies), this difference is not statistically significant (p = 
0.2; Figure 4A). Notably, in contrast to the macaques that received Z004 + Z021, plasma 
from macaques treated with Z004+Z021 (GRLR) antibodies did not enhance infection in 
vitro (Figure 4C). A K294R mutation, which is outside of the EDIII region targeted by the 
antibodies, was detected in one of the emerging viruses; however, RVPs containing K294R 
remained sensitive to both Z004 and Z021, suggesting that this is not a resistance mutation 
(Figure S4D). Thus, treatment of non-human primates with the combination of Z004 and 
Z021, two antibodies that target distinct but overlapping epitopes on the EDIII lateral ridge, 
suppresses and delays viremia in macaques infected intravenously with a high dose of ZIKV. 
Moreover, the combination of two antibodies prevents the emergence of ZIKV escape 
variants. Finally, antibodies whose Fc region is engineered to prevent enhancement provide 
similar levels of protection as antibodies with a wild-type Fc region.
DISCUSSION
We have determined the molecular mechanism of antigen binding by Z021 (this work) and 
Z004 (Robbiani et al., 2017), two potent neutralizing monoclonal antibodies against ZIKV 
and DENV1, and established that in combination, they prevent viral escape mutations in 
non-human primates.
It has been difficult to develop vaccines against the four DENV serotypes because of the 
complications associated with disease enhancement by cross-reactive antibodies (de Silva 
and Harris, 2018; Halstead, 2018; Screaton and Mongkolsapaya, 2018; Whitehead and 
Subbarao, 2018). ZIKV antibodies can cross-react with DENV and cause DENV 
enhancement in animal models. Therefore, it is anticipated that developing safe and effective 
ZIKV vaccines may be challenging (Andrade and Harris, 2018; George et al., 2017; Stettler 
et al., 2016).
Moreover, flaviviruses are RNA viruses that undergo high rates of error-prone replication, 
producing mutant variants that can be selected for resistance (Diamond, 2003; Drake et al., 
1998; Elena et al., 2000). Indeed, resistant viral variants arise in antibody-containing cell 
cultures infected with DENV (Lin et al., 1994; Lok et al., 2001; Zou et al., 2012), WNV 
(Beasley and Barrett, 2002; Chambers et al., 1998), YFV (Daffis et al., 2005), Japanese 
encephalitis virus (Shimoda et al., 2013), tick-borne encephalitis virus (Holzmann et al., 
1989), and ZIKV (Wang et al., 2017a). Resistance to monoclonal antibodies has also been 
docu mented in mice challenged with WNV (Sapkal et al., 2011) and rhesus macaques 
challenged with high doses of DENV (Lai et al., 2007; Magnani et al., 2017a). Our 
experiments are consistent with these earlier observations and extend them to ZIKV in non-
human primates by showing that administration of a single antibody leads to the selection of 
resistant viruses.
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To test the hypothesis that two antibodies might be more effective than one, we molecularly 
characterized Z021. Structural analysis of Z021 and comparison to Z004 (and related Z006) 
revealed that the two antibodies target overlapping but distinct sites. Z021 contacts the EDI-
EDIII hinge region of ZIKV and DENV1 EDIII with both its heavy and light chains, while 
Z004 and Z006 make more extensive contacts to the FG loop, including the E393-K394ZIKV 
motif (E384-K385DENV1). Because the E393-K394ZIKV motif is peripheral to the Z021 
epitope, viruses with mutations at these positions are likely to remain sensitive to Z021. 
These differences probably account for the efficacy of this combination of two antibodies 
despite the similarities in their target sites.
In high-dose challenge experiments, the combination of two monoclonal antibodies further 
decreased peak viremia compared to Z004 alone (Figure 4B). The antiviral effects of the 
antibodies were independent of their ability to bind to Fcγ receptors or to enhance infection 
in vitro. However, in contrast to prophylaxis with Z004 alone, where resistant variants were 
detected in both treated animals, there were no viral escape mutants in any of the six 
macaques treated with the combination of Z004 and Z021. Thus, the combination of these 
two antibodies is advantageous over Z004 alone due to their ability to prevent viral escape.
Z004 and Z021 target the EDIII lateral ridge, which is one of the key sites of viral 
attachment to cells, and both block infection in vitro. However, they do not provide sterile 
protection, despite high levels in circulation. One potential explanation for the disparity 
between in vitro and in vivo results is that ZIKV can attach to and infect cells through a 
number of different receptors, some of which may not be present in the Huh-7.5 cells used to 
measure infectivity in vitro (Heinz and Stiasny, 2017; Miner and Diamond, 2017). For 
example, virus attachment and entry via these receptors could be mediated through epitopes 
outside of the EDIII lateral ridge targeted by Z004 and Z021. Finally, viremia was delayed 
in 5 of the 8 treated macaques; an intriguing hypothesis is that during this time, ZIKV 
resides in and replicates in immune-privileged sites such as brain and testes that cannot be 
reached by antibodies (Iwasaki, 2017; Mital et al., 2011).
Our results differ from experiments where a single monoclonal was protective against low-
dose subcutaneous ZIKV challenge (Abbink et al., 2018). The difference may be due to a 
100-fold higher infectious dose of ZIKV delivered intravenously in our experiments. An 
additional possibility is that the animals in the low-dose experiments were only monitored 
for 7 days, which may not have been sufficient to document delayed infection seen after 
antibody treatment (Abbink et al., 2018). Whether other antibodies, single or in 
combination, will be completely protective after high-dose challenge remains to be 
determined but would be highly relevant for further clinical development, since the precise 
dose delivered by the Aedes aegypti vector is not known (Abbink et al., 2018; Magnani et 
al., 2017b).
Antibodies induced by vaccination or infection with any one of the DENV serotypes may 
fail to neutralize a second serotype and instead enhance dengue disease, with potentially 
catastrophic consequences. It is possible that dengue enhancement would also be mediated 
by cross-reactive antibodies elicited by vacci-nation against ZIKV (Andrade and Harris, 
2018; George et al., 2017; Stettler et al., 2016). Because of this uncertainty, passive antibody 
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administration for protection against ZIKV may represent a safe and practical alternative to 
vaccination during pregnancy and for infants and travelers, since antibodies can be 
engineered to prevent enhancement and have greatly extended half-lives by incorporating 
known Fc mutations (Gautam et al., 2018; Griffin et al., 2017; Ko et al., 2014; Robbie et al., 
2013; Zalevsky et al., 2010) (https://www.clinicaltrials.gov identifier NCT02878330). Our 
observations indicate that a combination of two antibodies targeting the EDIII lateral ridge is 
not sufficient for complete protection of high-dose ZIKV challenge, and combinations of 
additional antibodies are likely required.
STAR★METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Human recombinant 10–1074 Mouquet et al., 2012 N/A
Human recombinant Z004 Robbiani et al., 2017 N/A
Human recombinant Z021 Robbiani et al., 2017 N/A
Human recombinant Z015 Robbiani et al., 2017 N/A
Mouse anti-flavivirus group antigen, clone 
D1-4G2-4-15 (4G2)
Millipore Cat#MAB10216; RRID:AB_827205
Goat anti-human IgG, HRP-conjugated Jackson Immu no 
Research
Cat#109-035-098; RRID:AB_2337586
Goat anti-human IgG, HRP-conjugated GenScript Cat#A00166
Donkey anti-goat IgG, biotin-conjugated Jackson Immu no 
Research
Cat#705-065-147; RRID:AB_2340397
THE His Tag Antibody GenScript Cat#A00186; RRID:AB_914704
Goat anti-mouse IgG, HRP-conjugated Jackson Immu no 
Research
Cat#115-035-003; RRID:AB_10015289
Llama anti-human IgG (Captureselect) ThermoScientific Cat#7103322100
F(ab')2 Fragment Goat anti-human IgG, 
HRP-conjugated
Jackson ImmunoResearch Cat#109-036-088; RRID:AB_2337594
Bacterial and Virus Strains
E. coli BL21(DE3) New England Biolabs Cat#C2527H
Brazilian ZIKV Laboratory of M. Busch SPH2015
Puerto RicanZIKV CDC PRVABC59
DENV1 PUO-359 Laboratory of R.B. Tesh TVP-1140
Chemicals, Peptides, and Recombinant Proteins
Streptavidin-HRP Jackson Immu no 
Research
Cat#016-030-084
Neutravidin ThermoScientific Cat#31000
Poly-L-lysine solution Sigma-Aldrich Cat#P4707
Medium 199 Lonza Cat#12–109F
TRIzol-LS Thermo Fisher Scientific Cat#10296010
Jeffamine® ED-2001 pH 7.0 Hampton Research Cat#HR2–597
Fomblin Y oil Sigma-Aldrich Cat#317942–100G
Critical Commercial Assays
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REAGENT or RESOURCE SOURCE IDENTIFIER
Q5 site-directed mutagenesis kit New England Biolabs Cat#E0554S
QuikChange site-directed mutagenesis Agilent Technologies Cat#200524
Nunc MaxiSorp384-well ELISA plate Sigma-Aldrich Cat#P6491
SuperSignal ELISA Femto Substrate Thermo Fisher Scientific Cat#37075
Qiaamp viral RNAmini kit QIAGEN Cat#1020953
QIAGEN One-Step RT-PCR QIAGEN Cat#210210
Superscript III RT Thermo Fisher Scientific Cat#18080093
Nucleospin gel and PCR clean-up Macherey-Nagel Cat#740609
Deposited Data
Z021-ZIKV EDIII structure This paper PDB ID: 6DFI
Z021-DENV1 EDIII structure This paper PDB ID: 6DFJ
Experimental Models: Cell Lines
HEK293–6E National Research 
Council of Canada
NRC file 11565
Lenti-X 293T ATCC Cat#632180; RRID:CVCL_4401
Huh-7.5 Blight et al., 2002 N/A
Vero WHO Laboratory of S. 
Whitehead
MCB-P139
STAT1−/− Laboratory of J.-L. 
Casanova, Chapgier et al., 
2006
N/A
K-562 ATCC CAT#:CCL-243; RRID:CVCL_0004
Experimental Models: Organisms/Strains
Ifnar1−/− mice: B6.129S2-lfnar1tm1Agt/Mmiax The Jackson Laboratory JAX stock:32045
Rhesus Macaques (Macaca mulatta) California National 
Primate Research Center
Breeding colony
Oligonucleotides
Primers Table S3 this paper N/A
Recombinant DNA
IGγ1-, IGκ or IGλ-expression vectors Tiller et al., 2008 N/A
pWNVII-Rep-REN-IB Laboratory of T. Pierson N/A
pZIKV/HPF/CprME Laboratory of T. Pierson N/A
pZIKV/HPF/CprM*E* Robbiani et al., 2017 N/A
Wild typeZIKV EDIII expression vector Robbiani et al., 2017 N/A
Software and Algorithms
Prism (v7) GraphPad https://www.graph pad.com
Mosflm (v7.2.1, part of CCP4 package) Battye et al., 2011 http://www.ccp4.ac.uk
CCP4 (v7.0.032) Winn et al., 2011 http://www.ccp4.ac.uk
Ph en ix(v1.11.1–2575) Adams et al., 2010 http://www.phenix-online.org
Coot (vO.8.7, part of CCP4 package) Emsley and Cowtan, 
2004
http://www.ccp4.ac.uk
Antibody Database (v1.0) West et al., 2013 N/A
BIAcore T200 evaluation software GE Healhcare http://www.biacore.com/lifesciences/index.html
Other
Biacore T200 SPR system GE Healthcare CAT#:28975001
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REAGENT or RESOURCE SOURCE IDENTIFIER
CM5 sensor chip GE Healthcare CAT#:BR100399
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to and will be fulfilled by 
the Lead Contact, Davide Robbiani (drobbiani@rockefeller.edu). Sharing of reagents may 
require UBMTA agreements.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Macaques—Rhesus macaques (Macaca mulatta) were healthy juveniles or adults from the 
conventional type D retrovirus-free, SIV-free and simian lymphocyte tropic virus type 1 
antibody negative colony at the California National Primate Research Center (CNPRC). All 
animals were males except for two of the untreated controls (5021 and 5242). Animals were 
also confirmed to be antibody negative for West Nile virus. Animals were housed in 
accordance with Association for Assessment and Accreditation of Laboratory Animal Care 
Standards. We strictly adhered to Guide for the Care and Use of Laboratory Animals 
prepared by the Institute for Laboratory Animal Research. The study was approved by the 
Institutional Animal Care and Use Committee of the University of California Davis. When 
necessary for inoculations or sample collections, macaques were immobilized with 10 
mg/kg ketamine hydrochloride (Parke-Davis) injected intramuscularly after overnight 
fasting. Z004 and Z021 antibodies were administered to macaques at doses of 15 mg/kg 
body weight each by slow intravenous (i.v.) infusion (2ml/minute) 24 hours before 
saphenous vein i.v. inoculation with Brazilian ZIKV (105 PFU in 1 mL of RPMI-1640 
medium). Macaques were evaluated twice daily for clinical signs of disease including poor 
appetence, stool quality, dehydration, diarrhea, and inactivity. None of the animals that 
received the antibodies developed any clinical signs, suggesting a good safety profile. In 
contrast, one of four untreated macaques developed a severe transient skin rash in the 
axillary and inguinal areas on day 6, which peaked on day 8, was treated with topical 
antibiotics and steroids, and rapidly improved from day 10 onward. Animals were sedated 
for antibody administration (minus 24h), at time zero (virus inoculation), daily for 7 to 8 
days, and then every few days for sample collection. EDTA-anti-coagulated blood samples 
were collected using venipuncture.
Mice—Interferon-αβ receptor knock-out mice were obtained from The Jackson Laboratory 
(Ifnar1−/−; B6.129S2-Ifnar1tm1Agt/Mmjax) and were bred and maintained in the animal 
facility at Rockefeller University. Mice were specific pathogen free and on a standard chow 
diet. Both male and female mice (3–4 week old) were used for experiments and were equally 
distributed within experimental and control groups. 125 μg of monoclonal antibodies in 200 
μL of PBS were administered intraperitoneally to Ifnar1−/− mice one day before or one day 
after footpad infection with 1.25×105 plaque forming units (PFU) of ZIKV Puerto Rican 
strain in 50 μl. Mice were monitored for symptoms and survival over time. Animal protocols 
were in agreement with NIH guidelines and approved by the Rockefeller University 
Institutional Animal Care and Use Committee.
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Cell lines—Human embryonic kidney HEK293–6E suspension cells were cultured at 37°C 
in 8% CO2, shaking at 120 rpm. All other cell lines described below were cultured at 37°C 
in 5% CO2, without shaking. Green monkey Vero cells and human hepatocytes Huh-7.5 cells 
(Blight et al., 2002) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 1% nonessential amino acids (NEAA) and 5% FBS. Human Lenti-X 
293T cells and STAT1−/−, an SV40 large T antigen immortalized skin fibroblast line 
(Chapgier et al., 2006), were grown in DMEM 10% FBS. K-562 cells were maintained in 
RPMI supplemented with 10% FBS (ATCC, CCL-243). Huh-7.5 cells were developed in the 
Laboratory of Virology and Infectious Disease at Rockefeller University and verified by 
STR (standard tandem repeat). A seed-lot system is in place for these highly utilized cell 
lines, as well as for other lines obtained from the ATCC. The ATCC implements cell line 
authentication by STR DNA profiling. STAT1−/− cells are of unknown sex; HEK293–6E, 
Lenti-X 293T, K-562 and Vero are of female origin; Huh-7.5 are male.
Viruses—For in vitro experiments, ZIKV 2015 Puerto Rican PRVABC59 (Lanciotti et al., 
2016) was obtained from the CDC and passaged twice in human Huh-7.5 cells, and the Thai 
isolate of DENV1 PUO-359 (TVP-1140) was obtained from Robert Tesh and amplified by 
three passages in C6/36 insect cells. For mouse experiments, ZIKV 2015 Puerto Rican 
PRVABC59 was passaged once in STAT1−/− human fibroblasts. For macaque experiments, a 
2015 isolate of ZIKV from Brazil (strain SPH2015; GenBank accession number 
KU321639.1) was used. The strain was isolated from the plasma of a transfusion recipient 
and was passaged twice in VERO cells. Virus titrations were performed in African Green 
Monkey Kidney (VERO) cells using plaque assays. For PRVABC59, 200 μL of 10-fold 
serial dilutions of virus in OPTI-MEM were used to infect 400,000 cells seeded the previous 
day in a 6-well format. After 90 minutes adsorption, the cells were overlayed with DMEM 
containing 2% FBS with 1.2% Avicel and Penicilin/Streptomycin. Four days later the cells 
were fixed with 3.5% formaldehyde and stained with crystal violet for plaque enumeration. 
For SPH2015, 250 μL of 10-fold serial dilutions of samples in DMEM were inoculated onto 
confluent cell monolayers in duplicate in 6-well plates. After 60 minutes adsorption at 37°C, 
the cells were overlayed with MEM containing 2% FBS with 1.0% Penicilin/Streptomycin 
in 0.8% agar (liquefied 10% agar, ultrapure agarose [Invitrogen] diluted in 42°C MEM) and 
allowed to solidify, and incubated at 37°C with 5% carbon dioxide for 8 days. Cell 
monolayers were then fixed with 4% formalin for 30 minutes, agar plugs were removed, and 
0.025% gentian violet (Sigma) in 30% ethanol was overlaid in each well to stain viable cells. 
Viral titers were recorded as the reciprocal of the highest dilution where plaques are noted. 
The limit of detection of the assay was 1.6 log10 PFU/ml (Coffey et al., 2017; Robbiani et 
al., 2017).
METHOD DETAILS
Production of antibodies and Fabs—Z021, Z004, Z015 (Robbiani et al., 2017) and 
10–1074 (Mouquet et al., 2012) were prepared by transient transfection of mammalian 
HEK293–6E cells with equal amounts of immunoglobulin heavy and light chain expression 
vectors. The supernatant was harvested after seven days and the antibodies purified using 
Protein G Sepharose 4 Fast Flow. LPS was removed with TritonX-114 and the antibodies 
concentrated to 4.6 to 19 mg/ml in PBS. The GRLR (Horton et al., 2008; Lu et al., 2016), 
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LS (Ko et al., 2014; Zalevsky et al., 2010) and combined (GRLR/LS) modifications in the 
Fc portion of Z004 and Z021 human IgG1 expression plasmids (Tiller et al., 2008) were 
generated with Q5 site-directed mutagenesis kit (New England Biolabs) according to the 
company’s instructions and with the primers listed in Table S3. Fabs expressed for 
crystallography were expressed by transient transfection of HEK293–6E mammalian cells 
with equal amounts of C-terminally His-tagged Fab heavy chain (VH-CH1) and light chain 
expression vectors. The supernatant was harvested after six days and the Fabs were purified 
by affinity purification using HisTrap HP columns (GE Healthcare Life Sciences). Proteins 
were eluted with 300mM imidazole and then concentrated and further purified by size 
exclusion chromatography on a Superdex 200 Increase column (GE Healthcare Life 
Sciences).
Production of ZIKV proteins—Expression plasmids encoding the ZIKV mutant proteins 
EDIIIE393A/K394A, EDIIIE393D and EDIIIK394R were generated by modifying the wild-type 
EDIII expression plasmid (Robbiani et al., 2017) using QuikChange site-directed 
mutagenesis (Agilent Technologies) and confirmed by DNA sequencing. Primers used for 
mutagenesis are listed in Table S3. Mutant ZIKV EDIII proteins were expressed in E. coli 
BL21(DE3) (New England Biolabs), refolded from inclusion bodies, and purified (Robbiani 
et al., 2017; Sapparapu et al., 2016). Briefly, upon transformation with an appropriate EDIII 
protein-encoding expression vector, cells were grown to mid-log phase and induced with 
isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 hours. Upon lysis, the insoluble fraction 
containing the inclusion bodies was solubilized in buffer containing 6M guanidine 
hydrochloride, 100mM Tris-HCl pH 8.0, and 20mM β-mercaptoethanol and clarified by 
centrifugation. The solubilized inclusion bodies were then refolded using rapid dilution into 
400 mM L-arginine, 100 mM Tris-HCl (pH 8.0), 2 mM EDTA, and 5 and 0.5 mM reduced 
and oxidized glutathione at 4°C. The refolded protein was filtered, concentrated, and finally 
purified by size exclusion chromatography (Superdex 75; GE Healthcare) in 20mM Tris pH 
8.0, 150mM NaCl, 0.02% NaN3.
Generation and production of RVPs—Wild-type ZIKV Reporter Viral Particles 
(RVPs) with E proteins corresponding to Asian/American or African lineage were 
previously reported (Robbiani et al., 2017). Plasmids for expression of ZIKV CprME with E 
mutations were generated from plasmid pZIKV/HPF/CprM*E* (Robbiani et al., 2017), a 
derivative of pZIKV/HPF/CprME, a ZIKV C-prM-E expression construct provided by Ted 
Pierson (NIH) and engineered to contain unique BspHI and SacII restriction sites flanking 
the envelope region, allowing facile manipulation.
Assembly PCR-based site-directed mutagenesis was used to introduce the E393A-K394A 
double mutation or K294R single mutation into the envelope of ZIKV H/PF/2013 in 
pZIKV/HPF/CprM*E*, resulting in plasmids pZIKV/HPF/CprM*E*(E393A-K394A) or 
pZIKV/HPF/CprM*E*(K294R), respectively. The primers used for assembly PCR and 
mutagenesis are listed in Table S3. All PCR-derived plasmid regions were verified by 
sequencing.
RVPs bearing the ZIKV E protein with E393A-K394A or with K294R mutations were 
generated by cotransfection of Lenti-X-293T cells with plasmids pZIKV/HPF/
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CprM*E*(E393A-K394A) or pZIKV/HPF/CprM*E*(K294R) with pWNVII-Rep-REN-IB 
(Pierson et al., 2006; Robbiani et al., 2017). One μg of pWNVII-Rep-REN-IB (WNV 
replicon expression construct) and 3 μg of the appropriate flavivirus CprME expression 
plasmid were co-transfected with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. Lipid–DNA complexes were replaced after 4–5 h incubation 
with DMEM containing 20 mM HEPES and 10% FBS. After 48–72 h incubation at 34°C, 
RVP-containing supernatants were harvested, filtered through a 0.45 micron filter and frozen 
at −80°C.
In vitro neutralization and ADE assays—Plaque reduction neutralization test (PRNT) 
with ZIKV PRVABC59, and flow cytometry-based neutralization assay with DENV1 
PUO-359 were used to measure antibody neutralization activity in VERO cells (Robbiani et 
al., 2017). For ZIKV, diluent medium was Medium 199 (Lonza) supplemented with 1% 
BSA and Pen/Strep (BA-1 diluent). Briefly, 3- to 10-fold serial human antibody dilutions 
were added to a constant amount of Huh-7.5-ZIKV stock diluted in BA-1 diluent and 
incubated for 1 h at 37°C prior to application to VERO cells seeded at 400,000 cells per 6-
well the day prior. After 90 minutes adsorption, the cells were overlayed with DMEM 
containing 2% FBS with 1.2% Avicel and Pen/Strep. Four days later the cells were fixed 
with 3.5% formaldehyde and stained with crystal violet for plaque enumeration. PRNT50 
values were determined as the antibody concentration that resulted in 50% of the number of 
plaques obtained with the no antibody control. For DENV1, 5,000 VERO cells were seeded 
in 96-well plates. The next day, serial dilutions of antibody were incubated with DENV1 for 
1 hr at 37°C and applied to the cells (MOI = 0.02). After 3 days, the cells were fixed with 
2% formaldehyde and stained with the pan flavivirus anti-E protein 4G2 monoclonal 
antibody (2 μg/ml) in PBS containing 1% FBS and 0.5% saponin. Bound antibody was 
detected with Alexa Fluor 488-conjugated anti-mouse IgG antibody (1:1,000, Invitrogen) 
and the percentage of infected cells determined by flow cytometry. Percentages of cells 
infected with DENV1 in the presence of the different concentrations of antibody compared 
to cells infected with DENV1 in the absence of antibody was used to estimate the 50% 
reduction.
Neutralization of luciferase-encoding RVPs by antibodies using the ZIKV wild-type, 
E393A-K394A, K294R, and African mutant RVPs was performed with Huh-7.5 cells. 
15,000 cells were seeded in each well of a 96-well plate the day before infection in a volume 
of 100 μl. RVPs were diluted in BA-diluent, and 100 μL were added to 100 μL of triplicate 
samples of 3- or 10-fold serially diluted human antibody. After incubation for 1 h at 37°C, 
100 μL of the RVP/antibody mixture was added to the cells. After 24 h incubation at 37°C, 
the medium was removed and cells were lysed in 75 μL lysis buffer and 20 μL used for 
Renilla luciferase measurement using the Renilla Luciferase Assay System (Promega) 
according to the manufacturer’s instructions and read using a FLUOstar Omega 
luminometer (BMG LabTech). Neutralization capacity of the antibody was determined by 
the percentage of luciferase activity obtained relative to activity from RVPs incubated with 
BA-diluent alone (no antibody). Antibody dependent enhancement (ADE) of infection 
assays using antibodies or macaque plasma were similar to neutralization assays with RVPs, 
except that Fc-receptor bearing K-562 cells were used, and that the cells were in 96-well 
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plates coated with 0.01% poly-L-lysine (Sigma). The macaque plasma was serially diluted 
1:3 in BA-1 medium (1:50 – 1:328050, 9 dilutions in total). BA-1 medium is Medium 199 
(Lonza, 12–109F) supplemented with 1% BSA, 1400 mg/L sodium bicarbonate and 100 
U/ml Pen/Strep. The luciferase signal was normalized to the signal obtained with 10ng/ml of 
antibody Z004, which was present on the same plate.
ELISA assays
Fab ELISA: Figure 1D. 5 μg/mL ZIKV EDIII antigen (EDIIIwild-type, EDIIIE393A/K394A, 
EDIIIE393D or EDIIIK394R) was adsorbed to a Nunc MaxiSorp 384-well ELISA plate 
overnight at 4°C. The ELISA plate was blocked with 3% BSA in TRIS buffered saline with 
0.05% Tween-20 (TBS–T), washed with TBS-T, and then serial dilutions of Fab were added 
and incubated for 3 hours at room temperature. After washing the plate with TBS-T, bound 
Fab was detected using goat-anti-human IgG-HRP (GenScript; 1 hour, room temperature) 
and developed with SuperSignal ELISA Femto Substrate (Thermo Fisher).
Antigen competition ELISA: Figure 2G. Serial dilutions of Z004 or Z021 antibody were 
incubated overnight with nutation at 4°C in V-bottom 96-well plates in the presence of 
saturating concentrations of either wild-type EDIII, EDIIIE393A/K394A, or no protein control. 
In preliminary experiments, the saturating concentration of EDIII protein was determined as 
being approximately 1 μg/ml, and was increased to 10 μg/ml for the actual experiment. After 
overnight incubation the samples were added to ELISA plates that had been pre-coated with 
wild-type EDIII and the residual antibody binding to EDIII was detected using HRP-
conjugated goat anti-human IgG (Jackson ImmunoResearch; 1 hour, room temperature). The 
signal was enhanced by two amplification steps. First, after incubating with goat anti-human 
IgG-HRP (Jackson ImmunoResearch; 1 hour, room temperature) and washing with PBS 
containing Tween-20 0.05%, anti-goat IgG-biotin was added (Jackson ImmunoResearch; 1 
hour, room temperature). Second, after washing, streptavidin-HRP was added (Jackson 
ImmunoResearch; 1 hour, room temperature). After the final washes, the reaction was 
developed with ABTS substrate (Life Technologies).
Antibody competition ELISA: Figure 2I. Z004 or Z021 IgG (5 μg/mL) was adsorbed 
overnight at 4°C in a Nunc MaxiSorp 384-well ELISA plate. The ELISA plate was blocked 
with 3% bovine serum albumin (BSA) in TBS–T, and then 5 μg/mL of ZIKV EDIII was 
added and incubated for 3 hours at room temperature. The plate was washed with TBS-T to 
remove excess antigen, and Fab was then added at 25 μg/mL and incubated for 3 hours at 
room temperature. Bound His-tagged Fab was detected using THE His Tag Antibody 
(Genscript; 1 hour, room temperature), followed by goat-anti mouse IgG-HRP (Jackson 
ImmunoResearch; 1 hour, room temperature), and developed with SuperSignal ELISA 
Femto Substrate (Thermo Fisher). Relative light units were plotted for each IgG-antigen 
pair.
ELISA for human IgG detection in macaque: Figure S2. Neutravidin (ThermoScientific; 
2 μg/ml in PBS) was absorbed to high binding 96-well plates for overnight at 4°C. After 
washing the plate using PBS with 0.05% Tween-20 (PBS-T), the biotinylated anti-human 
IgG capture antibody was added (ThermoScientific; 2 mg/ml in PBS-T, 1 hour at room 
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temperature). Upon washes, the plates were blocked with 2% BSA in PBS-T (2 hours at 
room temperature), blotted, and then serial dilutions of the macaque plasma were added to 
the wells (5 steps of 1:4 dilutions in PBS-T, starting with 1:10). Each plate included serial 
dilutions of the standard, in duplicates (Z004 IgG, 11 steps of 1:3 dilutions in PBS-T, 
starting with 10 μg/ml). Plates were incubated for 1 hour at room temperature and washed 
prior to adding the detection reagent anti-human IgG-HRP (Jackson Immunoresearch; 1 
hour at room temperature). After the final washes, the reaction was developed with ABTS 
substrate (Life Technologies).
Surface plasmon resonance—FcγR and FcRn binding affinity of the Z004 Fc domain 
variants was determined by surface plasmon resonance (SPR) (Li et al., 2017; Wang et al., 
2017b). Briefly, all experiments were performed on a Biacore T200 SPR system (GE 
Healthcare) at 25°C in HBS-EP+ buffer (GE Healthcare; pH 7.4 for FcγRs, pH 6.0 for 
FcRn). Recombinant protein G (Thermo Fisher) was immobilized to the surface of a CM5 
sensor chip (GE Healthcare) using amine coupling chemistry at a density of 500 resonance 
units (RU). Fc variants of the Z004 antibody were captured on the Protein G-coupled surface 
(250 nM injected for 60 s at 20 μl/min) and recombinant human FcγR ectodomains (7.8125 
– 2000 nM; Sinobiological) or FcRn/b2 microglobulin (1.95 – 500 nM; Sinobiological) were 
injected through flow cells at a flow rate of 20 μl/min. Association time was 60 s followed 
by a 600 s dissociation step. At the end of each cycle, the sensor surface was regenerated 
with 10 mM glycine, pH 2.0 (50 μl/min; 40 s). Background binding to blank immobilized 
flow cells was subtracted and affinity constants were calculated using BIAcore T200 
evaluation software (GE Healthcare) using the 1:1 Langmuir binding model.
Processing of macaque blood samples—EDTA-anticoagulated blood was processed 
immediately by centrifugation for 10 minutes at 800 X g to separate plasma from cells. The 
plasma was spun an additional 10 minutes at 800 X g to further remove cells, and aliquots 
were immediately frozen at −80°C. The cellular blood fraction was diluted with PBS and 
layered on lymphocyte separation medium (MP Biomedicals) and spun for 30 m at 800 g to 
isolate peripheral blood mononuclear cells that were washed and then cryopreserved for 
future analyses. Complete blood counts (CBC) were performed on EDTA-anticoagulated 
blood samples; samples were analyzed using a Pentra 60C+ analyzer (ABX Diagnostics); 
differential counts were determined manually using Wright-Giemsa staining.
Isolation and quantitation of viral RNA—Zika virus RNA was isolated from plasma 
and measured by RT-qPCR according to methods described previously (Lanciotti et al., 
2008) and detailed below, which were modified to increase the initial volume of sample 
tested from 140 to 300 μL (when available) to increase sensitivity. RNA was extracted from 
plasma according to manufacturer’s recommendations using an Applied Biosystems 
MagMax 96-well Viral RNA kit and the AM1836 DW200 STD program on a MagMax 
Express 96-Deep Well Magnetic Particle Processor (ThermoFisher, Waltham, MA). All 
RNA extracts were eluted in 60 μL of DEPC-treated water for storage at −80°C prior to 
quantification. ZIKV RNA was measured in triplicate by reverse transcription RT-qPCR on 
an Applied Biosystems ViiA 7 machine using the Taqman Fast Virus 1-Step Master Mix 
(Thermo) and published primers (ZIKV 1086, ZIKV 1162c, and ZIKV 1107-FAM; 
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(Lanciotti et al., 2008)) with 9.6 μL of RNA. Levels of ZIKV RNA in samples are expressed 
as mean log10 copies per ml plasma.
Virus sequencing—For detection of virus escape mutations in macaques, ZIKV RNA 
was extracted at peak viremia from plasma using the Qiaamp viral RNA mini kit following 
the manufacturer’s recommendations with elution of RNA in water. QIAGEN One-Step RT-
PCR was performed using either of two primer sets targeting sequences surrounding the 
ZIKV EDIII region (see Table S3), with 50°C for 30 m, 95°C for 15 m. Next, 40 cycles of 
each of the 3 steps were performed: 94°C for 1 m, 58°C for 1 m, 72°C for 1m15s, followed 
by final extension of 72°C for 10 m. RT-PCR amplicons were visualized on 1% agarose gels 
stained with ethidium bromide and sequenced after purification using the Qiaquick PCR 
purification kit. Sequences were called based on clean chromatograms sequenced with the 
primers used for amplification. Due to very low levels of viremia, reliable EDIII sequence 
information was obtained for only 210 out of 303 nucleotides from macaque 6082 
(Z004+Z021), and no sequencing was possible from macaque 6146 (Z004+Z021 GRLR). 
Viral sequences in mice were from blood. RNA was extracted from TRIzol-LS (Life 
Technologies) and reverse transcribed with Superscript III RT (Thermo Fisher Scientific) 
and random primers according to the company’s protocol prior to PCR amplification of the 
ZIKV EDIII region with primers DFRp1284 and DFRp1469 followed by PCR clean-up with 
Nucleospin (Macherey-Nagel) and direct sequencing with primer DFRp1283. Where 
necessary, a second round of nested PCR was performed with primers DFRp1472 and 
DFRp1470. The primers sequence is listed in Table S3.
Crystallization and structure determination
Z021-ZIKV EDIII complex: The complex for crystallization was produced by mixing 
Z021 Fab and ZIKV EDIII at a 1:1 molar ratio, incubating at room temperature for 1–2 
hours, and concentrating to 14.1 mg/mL. Crystals of Z021 Fab–ZIKV EDIII complex (space 
group P212121; a = 73.88Å, b = 105.62Å, c = 107.24Å; one molecule per asymmetric unit) 
were obtained by combining 0.2 μL of protein complex with 0.2 μL of 0.1M HEPES pH 7.0, 
29% PEG 1000 in sitting drops at 22°C. Crystals were cryoprotected with 25% glycerol.
X-ray diffraction data were collected at Advanced Photon Source (APS) beamline 23-ID-D 
using a Dectris Pilatus 6M detector. The data were integrated using Mosflm (Battye et al., 
2011) and scaled using CCP4 (Winn et al., 2011). The Z021-ZIKV EDIII complex structure 
was solved by molecular replacement using the VHVL and CHCL domains from our Z021-
DENV1 EDIII complex and ZIKV EDIII from PDB 5KVG as search models in Phenix 
(Adams et al., 2010). The model was refined to 2.48 Å resolution using an iterative approach 
involving refinement in Phenix and manual rebuilding into a simulated annealing composite 
omit map using Coot (Emsley and Cowtan, 2004). The final model (Rwork = 18.2%; Rfree = 
22.8%) contains 537 protein residues and 68 water molecules. 96%, 4%, and 0.2% of the 
protein residues were in the favored, allowed, and outlier regions, respectively, of the 
Ramachandran plot. Residues that are disordered and not included in the model are: HC 
residues 216–219 and the 6X His tag; LC residue 214, and ZIKV EDIII residues 299–302 
and 405–407. The accession number for the Z021-ZIKV EDIII complex crystal structure 
reported in this paper is PDB: 6DFI.
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Z021-DENV1 EDIII complex: The complex for crystallization was produced by mixing 
Z021 Fab and DENV1 EDIII at a 1:1 molar ratio, incubating at room temperature for 1–2 
hours, and concentrating to 12.25 mg/mL. Crystals of Z021 Fab–DENV1 EDIII complex 
(space group C2221; a = 60.54Å, b = 91.60Å, c = 187.14Å; one molecule per asymmetric 
unit) were obtained by combining 0.2 μL of protein complex with 0.2 mL of 0.1M sodium 
citrate pH 4.8, 28% Jeffamine® ED-2001 pH 7.0 in sitting drops at 22°C. Crystals were 
cryoprotected with Fomblin Y oil. X-ray diffraction data were collected at Stanford 
Synchrotron Radiation Lightsource (SSRL) beamline 12–2 using a Dectris Pilatus 6M 
detector. The data were integrated using Mosflm (Battye et al., 2011) and scaled using CCP4 
(Winn et al., 2011). The Z021-DENV1 EDIII complex structure was solved by molecular 
replacement using the VHVL and CHCL domains from PDB 4YK4 and DENV1 EDIII from 
PDB 4L5F as search models in Phenix (Adams et al., 2010). The model was refined to 
2.07Å resolution using an iterative approach involving refinement in Phenix and manual 
rebuilding into a simulated annealing composite omit map using Coot (Emsley and Cowtan, 
2004). The final model (Rwork = 18.4%; Rfree = 23.2%) contains 532 protein residues and 
126 water molecules. 96%, 4%, and 0% of the protein residues were in the favored, allowed, 
and disallowed regions, respectively, of the Ramachandran plot. Residues that are disordered 
and not included in the model are: HC residues 215–219 and the 6X His tag; LC residues 
213–214. The Z021-DENV1 EDIII complex crystal structure has been deposited in the 
Protein Data Bank with accession code PDB: 6DFJ.
QUANTIFICATION AND STATISTICAL ANALYSIS
Information on the statistical tests used, and the exact values of n and what it represents can 
be found in the Results and Figure Legends. Unless otherwise noted, statistical analysis was 
with Prism software. Luciferase- and flow cytometry-based neutralization and enhancement 
assays were performed in triplicate wells, and the antibody concentration (IC50) that 
neutralized 50% of the virus or RVP inoculum was calculated by nonlinear, dose-response 
regression analysis. Representatives of at least two independent experiments are shown 
throughout, except for ZIKV neutralization (where the mean of two experiments is shown), 
and for the measurement of ADE in macaque plasma (where only one assay was performed 
due to limited amounts of available plasma). The levels of plasma viremia were measured in 
triplicates. The Mantel-Cox test was applied to analyze disease and survival in mice 
infection experiments and the Mann-Whitney test to determine the significance of the 
difference in peak viremia in macaques.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the structural data reported in this paper are PDB: 6DFI (Z021-
ZIKV EDIII complex) and PDB: 6DFJ (Z021-DENV1 EDIII complex).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Monoclonal antibodies are tested in macaques challenged with high-dose 
Zika virus
• A single monoclonal antibody selects for Zika virus escape mutants
• A combination of two antibodies suppresses viremia and prevents escape 
mutants
• Antibodies engineered to avoid enhancement confer similar levels of 
protection
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Figure 1. Administration of Z004 Alone Leads to the Emergence of Resistant ZIKV in Rhesus 
Macaques (Macaca mulatta)
(A) Macaques were administered monoclonal antibody Z004 (red) 1 day before intravenous 
inoculation with 105 PFU of ZIKV or were untreated (black). The graph shows plasma viral 
RNA levels of ZIKV over time as determined by qRT-PCR.
(B) ZIKV mutations emerging in macaques treated with Z004 alone. An alignment in the 
region of residues E393-K394 (bold) within the EDIII is shown at the top, and 
chromatograms of the PCR amplicons showing the mutations (indicated by red arrows) are 
shown at the bottom. Amino acid changes compared to the inoculum sequence are 
highlighted in red. In macaque 6414, E393D and K394R are on separate viral RNAs, as 
determined by sequencing of the cloned amplicon.
(C) The epitope of ZIKV EDIII recognized by the Z004-related antibody Z006 is shown in 
red (PDB: 5VIG). The E393-K394 residues are highlighted.
(D) Impaired binding of Z004 to the EDIII escape mutants. ELISA demonstrates reduced 
binding of Z004 Fab to EDIIIK394R and EDIIIE393D. The positive control antibody Z015 
recognizes an epitope that is independent of the E393 and K394 residues. Data are presented 
as mean ± SD of triplicates, and a representative of two experiments is shown.
See also Figure S1.
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Figure 2. Z021 Neutralizes ZIKV and Recognizes a Different Epitope than Z004
(A) Z021 neutralizes ZIKV RVPs corresponding to the African strain. Neutralization by 
Z004 is shown alongside for comparison. Data are presented as mean ± SD of triplicates.
(B) Z021 is effective against ZIKV in vitro. ZIKV neutralization was determined by 
measuring the ability of increasing concentrations of Z021 to reduce the number of plaques 
in a PRNT assay. Data are presented as mean ± SD of two independent experiments.
(C) Z021 is effective against DENV1 in vitro. DENV1 neutralization was assessed by 
measuring the relative number of 4G2-positive infected cells by flow cytometry. Data are 
presented as mean ± SD of triplicates.
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(A–C) Values are relative to control antibody 10–1074. Antibody Z004 is shown alongside 
for comparison (Robbiani et al., 2017). A representative of two independent experiments is 
shown.
(D–F) Z021 protects mice from ZIKV disease. Layout of the experiment (D). Ifnar1−/− mice 
were treated with Z021 or control 10–1074 antibody 1 day before (E) or 1 day after (F) 
challenge with ZIKV in the footpad (f.p.). Mice were monitored for symptoms and survival. 
The graph indicates death or symptoms. Survival: p < 0.0001 (pre-exposure) and p = 0.0002 
(post-exposure). Symptoms: p = 0.0002 (pre-exposure) and p = 0.0006 (post-exposure; 
Mantel-Cox test). The number of mice used in pre-exposure experiments was 13 (Z021) and 
11 (10–1074); for post-exposure experiments, 12 animals were used in each group. Data 
represent two combined experiments.
(G) Residues E393-K394 of ZIKV EDIII are not required for Z021 binding. Graphs show 
ELISA binding to ZIKV EDIII by increasing concentrations of antibody Z004 (left) or Z021 
(right) after blocking with wild-type EDIII or EDIIIE393A/K394A.
(H) Residues E393-K394 are not required for ZIKV neutralization by Z021. Graphs show 
neutralization of ZIKV luciferase RVPs by Z021 and Z004 using wild-type RVPs (left) or 
RVPs mutated at the Z004-binding site (E393A-K394A; right). Data are presented as mean 
± SD of triplicates, and a representative of two experiments is plotted. Values are relative to 
no antibody control.
(I) Z004 and Z021 antigen-binding fragments (Fabs) cannot bind to ZIKV EDIII 
simultaneously. ZIKV EDIII antigen was immobilized in an ELISA with either Z004 IgG 
(left) or Z021 IgG (right) and then incubated with a His-tagged Fab of Z021, Z004, or Z015. 
Fab binding to the IgG-immobilized ZIKV EDIII was detected by anti-His secondary 
antibody. The positive control Z015 Fab recognizes an epitope that is distinct from that of 
both Z021 and Z004 (Robbiani et al., 2017). Data are presented as mean ± SD of 
quadruplicates and are representative of two experiments.
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Figure 3. Comparison of Z021 and the Z004-Related Antibody, Z006, Binding to the ZIKV and 
DENV1 EDIII Domain
(A) Superimposition of the Z021 Fab-ZIKV complex with the Z021 Fab-DENV1 complex. 
The EDI-EDIII hinge region and loops of the ZIKV EDIII (bright colors) and DENV1 EDIII 
(light colors) within the epitope are highlighted, and the side chains of E394 and K395 
residues of ZIKV are shown in sticks. The two views are related by a 90° rotation.
(B) Superimposition of Z021 Fab-ZIKV EDIII complex with Z006 Fab-ZIKV EDIII 
complex (PDB: 5VIG). The VHVL of Z021 Fab is rotated ~45° around an axis near CDRH2 
compared to the Z006 VHVL bound to the same antigen.
(C) The epitopes of Z021 and Z006 on ZIKV EDIII are overlapping but distinct. EDIII 
residues within4Å of Z021 Fab (blue), Z006 Fab (red), or both (purple) are highlighted on a 
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surface representation of the ZIKV EDIII from the Z021-ZIKV EDIII complex structure. 
The E393-K394ZIKV motif is outlined. The two views are related by a 90° rotation.
See also Tables S1 and S2.
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Figure 4. The Combination of Z004 and Z021 Antibodies Protects ZIKV-Challenged Macaques
(A) Macaques were administered a combination of Z004 and Z021 (brown) or a 
combination of the same antibodies containing mutations in the Fc that prevent Fcγ receptor 
binding (Z004-GRLR and Z021-GRLR; green) 1 day before intravenous inoculation with 
105 PFU of ZIKV. The graph shows plasma viral RNA levels of ZIKV over time as 
determined by qRT-PCR. Untreated controls are the same as in Figure 1.
(B) Peak viral RNA loads in plasma are decreased by antibody treatment (based on Figures 
1A and 4A). The p value was determined with the Mann-Whitney test. The gray bar 
represents the peak viral load of both Z004 + Z021 and Z004 + Z021 (GRLR) groups 
combined.
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(C) Plasma of macaques treated with the combination of Z004-GRLR and Z021-GRLR fails 
to induce antibody-dependent enhancement (ADE) of infection in K-562 cells by ZIKV 
RVPs. Dilutions of macaque plasma (1:50–1:328,050; 9 dilutions in total) obtained at 
different time points were assayed for the ability to induce ZIKV RVP infection (see STAR 
Methods). n.d., not determined due to lack of plasma sample.
See also Figures S2–S4.
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